✦ LIBER ✦

TCT-592 Lower Five Year Event Rates In The Genous Endothelial Progenitor Cell Capturing Stent Compared With A Drug Eluting Stent In De-novo Coronary Artery Lesions With A High-risk Of Restenosis; A Randomized Controlled Trial

✍ Scribed by Woudstra, Pier; Beijk, Marcel A.; Koch, Karel T.; Baan, Jan; Vis, Marije M.; Henriques, Jose P.; Piek, Jan; Tijssen, Jan G.; de Winter, Robbert J.

Book ID: 126863676
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 160 KB
Volume: 64
Category: Article
ISSN: 1558-3597
DOI: 10.1016/j.jacc.2014.07.656

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1-Year Outcome of TRIAS HR (TRI-Stent Ad

1-Year Outcome of TRIAS HR (TRI-Stent Adjudication Study–High Risk of Restenosis): A Multicenter, Randomized Trial Comparing Genous Endothelial Progenitor Cell Capturing Stents With Drug-Eluting Stents

✍ Margo Klomp; Marcel A. Beijk; Chetan Varma; Jacques J. Koolen; Emmanuel Teiger; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 616 KB

Two-year follow-up of the genous™ endoth

Two-year follow-up of the genous™ endothelial progenitor cell capturing stent versus the taxus liberté stent in patients with De Novo coronary artery lesions with a high-risk of restenosis : A randomized, single-center, pilot study

✍ Marcel A.M. Beijk; Margo Klomp; Nan van Geloven; Karel T. Koch; José P.S. Henriq 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

Late-Term Clinical Outcomes With Zotarol

Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)

✍ David E. Kandzari; Laura Mauri; Jeffrey J. Popma; Mark A. Turco; Paul A. Gurbel; 📂 Article 📅 2011 🏛 American College of Cardiology 🌐 English ⚖ 704 KB